Last mentioned: Mar 23, 2026
Structure Therapeutics (GPCR) has seen its shares decline 28% in early 2026, even as B Group, Inc. revealed a new $6.26 million position in the clinical-stage biotech. The company remains a key contender in the competitive oral GLP-1 market with its lead candidate GSBR-1290 showing strong mid-stage clinical results.
Structure Therapeutics (GPCR) has faced a 28% year-to-date decline in 2026, even as institutional investor B Group, Inc. disclosed a new $6.26 million position. The clinical-stage biotech remains a high-stakes player in the competitive oral GLP-1 market with its lead candidate, GSBR-1290.
Structure Therapeutics (GPCR) has experienced a 28% year-to-date decline in 2026, contrasting with its triple-digit gains over the previous year. Despite the recent sell-off, B Group, Inc. has initiated a $6.26 million position in the clinical-stage biotech, highlighting continued institutional interest in its oral GLP-1 pipeline.
The FDA approval of Novo Nordisk's first oral GLP-1 for weight loss has sparked a rally in NVO shares, offering a needle-free alternative to Wegovy. This development, coupled with a strategic partnership with Hims & Hers, positions the company to maintain its dominant market share against rising competition.